{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.540","upperLimit":"0.937","value":"0.711"}]}],"title":"OS at year 1"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.316","upperLimit":"0.778","value":"0.495"}]}],"title":"OS at year 2"}],"denoms":[{"counts":[{"groupId":"OG000","value":"23"}],"units":"Participants"}],"description":"Survival is defined as the duration of time from start of treatment to time of death, up to three years from the start of study treatment. Overall Survival (OS) is reported below as the proportion of patients who are alive at 1 and 2 years after starting treatment.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive romidepsin IV over 4 hours on days 1, 8, and 15 and lenalidomide PO QD on days 1-21. Treatment repeats every 28 days for up to 1 year in the absence of disease progression or unacceptable toxicity.\n\nromidepsin: Given IV\n\nlenalidomide: Given PO\n\nlaboratory biomarker analysis: Correlative studies","id":"OG000","title":"Treatment (Romidepsin, Lenalidomide)"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Reported at 1 and 2 years after the start of treatment","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"OS Probablilty"}